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Abstract
Background: The concordance of microalbuminuria and diabetic retinopathy (DR) has been well reported in
persons with type 1 diabetes; however, for type 2 diabetes, there is paucity of data especially from population-
based studies. The aim of this study was to estimate the prevalence of albuminuria (micro - and macroalbuminuria)
among persons with type 2 diabetes and determine its role as a risk factor for presence and severity of DR.
Methods: A population-based cross sectional study was conducted in cohort of 1414 subjects with type 2 diabetes
from Chennai metropolis. All the subjects underwent comprehensive eye examination including 45 degrees four-
field stereoscopic digital photography. DR was clinically graded using Early Treatment Diabetic Retinopathy Study
scales. A morning urine sample was tested for albuminuria. Subjects were considered to have microalbuminuria, if
the urinary albumin excretion was between 30 and 300 mg/24 hours, and macroalbuminuria at more than 300
mg/24 hours. The statistical software used was SPSS for Windows, Chicago, IL. Student t-test for comparing
continuous variables, and c
2 test, to compare proportions amongst groups were used.
Results: The prevalence of microalbuminuria in the study subjects was 15.9% (226/1414), and that of
macroalbuminuria, 2.7% (38/1414). Individuals with macroalbuminuria in comparison to micro- or
normoalbuminuria showed a greater prevalence of DR (60.5% vs. 31.0% vs. 14.1%, p < 0.001), and also a greater
severity of the disease (60.9% vs. 21.4 vs. 9.9, p < 0.001).
Conclusions: Every 6
th individual in the population of type 2 diabetes is likely to have albuminuria. Subjects with
microalbuminuria were around 2 times as likely to have DR as those without microalbuminuria, and this risk
became almost 6 times in the presence of macroalbuminuria.
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Background
In the year 2000, there were around 171 million people
with diabetes globally, and by 2030, it is estimated that
this number would increase to 366 million [1]. As the
number of persons with diabetes increases, the develop-
ment of microvascular complications like retinopathy,
nephropathy and neuropathy also rises. These microvas-
cular complications are linked to the duration of
diabetes mellitus, poor glycemic control and systolic
hypertension [2]. The magnitude of damage caused by
these microvascular complications of diabetes stresses
the need for sensitive markers of screening for retinopa-
thy and nephropathy. The sensitive marker for the
detection of diabetic nephropathy is to estimate excre-
tion of microalbumin in urine; and for the detection of
diabetic retinopathy (DR), to have a fundus evaluation
after pupillary dilatation [3,4].
According to a report by the World Health Organiza-
tion (WHO), the prevalence rates of nephropathy after
15 years of diabetes ranged between 17.7 and 56.6% in
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responsible for 4.8% of the 37 million cases of blindness
throughout the world [5]. The concordance of microal-
buminuria and DR has been well reported in persons
with type 1 diabetes [6-8]; however, for type 2 diabetes,
there is paucity of data especially from population-based
studies regarding the association of microalbuminuria
with DR [9-14]. The present population based study was
carried out to estimate the prevalence of albuminuria
(micro- and macro-) in type 2 diabetes mellitus and
report its influence as a risk factor for the presence and
severity of DR.
Materials and methods
Study subjects were recruited from the Sankara Nethra-
laya Diabetic Retinopathy Epidemiology and Molecular
Genetic Study (SN-DREAMS), which was a population-
based cross sectional study. The study design and
research methodology of SN-DREAMS 1 is described in
detail elsewhere [15]. The study area was Chennai
metropolis with a population of 4.3 million, distributed
in 155 divisions of ten zones.
A computed sample size of 5830 individuals was esti-
mated assuming the prevalence of DR in the general
population to be 1.3%, with a relative precision of 25%,
ad r o p - o u tr a t eo f2 0 % ,a n dad e s i g ne f f e c to f2 .I n c l u -
sion criteria included Individuals aged 40 years or above
or turning 40 in the current year and residing for a
minimum of six months at the same residence. Indivi-
duals residing for a period of less than six months at
the same residence, temporary residents (whose perma-
nent residence is elsewhere), a resident who dies after
the enumeration but prior to examination, and those
who cannot be contacted after five attempts by the
social worker at their residence were excluded from the
study.
Thus, 5999 subjects from the general population aged
>40 years were enumerated. To ensure that data is col-
lected from all socioeconomic groups, multistage ran-
dom sampling was stratified, on the basis of economic
criteria. To avoid patient selection bias, sampling was
done in two stages: selection of divisions and selection
of study subjects. Selection of divisions was done using
computer generated random numbers; ensuring that
one division per one corporate zone is represented in
the sample. Eligible study subjects were then randomly
selected from each division.
Of the 5999 subjects enumerated, 1414 persons identi-
fied with diabetes (both known and newly diagnosed)
were analyzed for the study (96.20% response rate for
first fasting blood sugar estimation, 85.60% response
rate for base hospital examination, 8.7% turned out as
non diabetic after second blood sugar and 0.78% of ret-
inal images were un-gradable). Subjects with type 2
diabetes were identified based on the American Diabetes
Association criteria [16]. Persons with known diabetes
were previously diagnosed cases of diabetes whether or
not they were using either oral anti-glycemic drugs or
insulin or both. Persons with newly-diagnosed diabetes
were those who had their fasting blood glucose level
≥110 mg/dl on two separate days. The study was
approved by the Institutional Review Board, and written
informed consent was obtained from subjects as per the
Helsinki declaration. In order to ensure that the diag-
nostic measurements of glucose were quality assured,
many quality control measures were taken. A compre-
hensive instruction manual and a start-up training ses-
sion helped to standardize all the examination and
diagnostic procedures. The glucometer was calibrated
every day and its reproducibility was assessed by mea-
suring the blood glucose for the same patient six times
and also with two machines. The collected data was
scrutinized manually before its entry into the computer.
The measurements were centralized at the base hospital.
Albuminuria estimation was done by a semi-quantita-
tive procedure (Bayer Clinitek 50 Urine Chemistry Ana-
lyzer) with the first morning urine sample [17]. The
Clinitek Microalbumin strip contains two reagent areas
that test for albumin and creatinine in urine and provide
semiquantitative results. In this study, only the albumin
results were used. The albumin test is based on dye
binding, using a high-affinity sulfonephthalein dye. At a
constant pH, the development of any blue color is due
to the presence of albumin. The resulting strip color
ranges from pale green to aqua blue. The results were
read with the use of the Clinitek 50 Urine Chemistry
Analyzer (Bayer Health- Care, Elkhart, Ind., USA). Sen-
sitivity and specificity for microalbuminuria diagnosis
have been reported to be 100 and 81% for Clinitek
Microalbumin [18]. The diagnostic performance of mea-
suring UAC in a spot morning urine sample in predict-
ing microalbuminuria in subsequent 24-hour urine
collections has been reported to be satisfactory, and,
moreover, comparable to that of measuring ACR [19].
Subjects were considered to have microalbuminuria, if
the Urinary Albumin Excretion (UAE) was between 30
and 300 mg/24 hours, and macroalbuminuria at more
than 300 mg/24 hours [20]. Glycosylated hemoglobin
(HbA1c) fractions were estimated by using Merck Micro
Lab 120 semi-automated analyzer (Bio-Rad DiaSTAT
HbA1c Reagent Kit) [16]. Severity of DR was clinically
graded using Early Treatment Diabetic Retinopathy
Study scales [21]. Retinal photographs were taken after
pupillary dilatation (Carl Zeiss Fundus Camera, Visu-
camlite, and Jena, Germany); all patients underwent 45°
four-field stereoscopic digital photography. For those
who showed evidence of any DR, additional 30° seven-
field stereo digital pairs were taken. All photographs
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fashion; the grading agreement was good (k = 0.83).
When the evaluation of the two independent observers
of DR did not agree, a third observer was referred to.
Statistical analyses were performed using the statistical
software (SPSS for Windows, ver.13.0 SPSS Science,
Chicago, IL). The results were expressed as mean ± SD
if the variables were continuous, and as percentage, if
categorical. Student t-test for comparing continuous
variables, and c
2 test, to compare proportions amongst
groups were used. Individuals with newly-diagnosed dia-
betes were given a value of zero for duration of diabetes.
P value of ≤0.05 was considered as significant. Both uni-
variate and multivariate logistic regression analyses were
performed to study the effect of various risk factors
using microalbuminuria and macroalbuminuria as
dependent variables. From the univariate analysis, vari-
ables with p values ≤0.05 and those, which were already
established as risk factors, were included in the multi-
variate logistic regression analysis to derive at the parsi-
monious model. These variables included age, duration
of diabetes, body mass index, systolic and diastolic
blood pressure, and HbA1c.
Results
Table 1 provides the definitions of the terms used in the
study.
Table 2 shows the prevalence of micro - and macroal-
buminuria in the study population. Out of 1414 sub-
jects, 1166 were known cases of diabetes and 248 were
having newly diagnosed diabetes. Overall, the prevalence
of microalbuminuria in the study subjects was 226 out
of 1414, 15.9% (95% CI: 13.9-17.8), and that of macroal-
buminuria was 38 out of 1414, 2.7% (95% CI: 1.8-3.5).
T h ep r e v a l e n c eo fm i c r o a l b u m i n u r i aw a s1 9 1o u to f
1166, 16.4% in individuals with known diabetes, and 35
out of 248, 14.1%, in those with newly diagnosed dia-
betes (p = 0.38). However, the prevalence of macroalbu-
minuria showed statistically significant differences
between these 2 groups (3.1% vs. 0.8%, p = 0.04).
Table 3 summarizes the clinical characteristics among
the study population with regard to normo -, micro -
and macroalbuminuria. The mean age of the total study
population (n = 1414) was 56.3 ± 10 yrs; 750 (53.04%)
were men. Several clinical parameters showed highest
value in individuals with macroalbuminuria followed by
micro - and normoalbuminuria. These parameters
included age, duration of diabetes and systolic blood
pressure (p < 0.001). The body mass index (BMI) (Kg/
m
2) was the lowest in individuals with macroalbumi-
nuria compared to micro - and normoalbuminuria (23.5
± 3.8 vs. 24.9 ± 4.5 vs. 25.5 ± 3.9, p = 004). The diasto-
lic blood pressures were higher in those individuals
with macro - or microalbuminuria compared to those
with normoalbuminuria (83.8 ± 12.9 vs. 84.0 ± 11.5 vs.
81.5 ± 11.2, p = 005), and so was true for HbA1c (9.0 ±
2.3 vs. 9.0 ± 2.3 vs. 8.0 ± 2.1, p < 0.001). Individuals
with macroalbuminuria in comparison to micro - or
normoalbuminuria showed a greater prevalence of DR
(60.5% vs. 31.0% vs. 14.1%, p < 0.001), and also a
greater severity of the disease (60.9% vs. 21.4 vs. 9.9, p
< 0.001). There was no significant association between
serum lipids and albuminuria (p = 0.299 for total cho-
lesterol, p = 0.119 for HDL and p = 0.896 for
triglycerides).
Results of regression analysis of risk factors related to
albuminuria are shown in Table 4. For microalbumi-
nuria, the significant variables included increase in age
per year Odds Ratio (OR) 1.01 (95% CI: 1.00-1.04),
increase in systolic blood pressure per mm of Hg OR
1.01 (95% CI: 1.00-1.02), increase in HbA1c per gm%
OR 1.18 (95% CI: 1.11-1.26), presence of DR OR 2.10
(95% CI: 1.46-3.01) and sight-threatening DR OR 2.49
(95% CI: 1.15-5.37). For macroalbuminuria, significant
variables included increase in systolic blood pressure per
mm of Hg OR 1.02 (95% CI: 1.00-1.04), presence of DR
OR 6.50 (95% CI: 3.11- 13.61), and sight-threatening DR
OR 14.19 (95% CI: 5.31-37.96). Decreased BMI was
associated with macroalbuminuria OR 0.89 (95% CI:
0.80-0.98).
Table 1 Definitions used in the Study
Sno Variable Definition
1 Albuminuria The patient was considered to have normoalbuminuria, if Urinary Albumin Excretion (UAE) was < 30 mg/24
hour; microalbuminuria, if UAE was 30-300 mg/24 hours, and macroalbuminuria if UAE was >300 mg/24
hours
2 Diabetes Mellitus Persons with known diabetes were those who were using either oral anti-glycemic drugs or insulin or both.
Persons with newly-diagnosed diabetes were those who had their fasting blood glucose level ≥110 mg/dl
on two separate days.
3 Non-sight threatening Diabetic
Retinopathy
Non-sight threatening diabetic retinopathy included cases of mild or moderate non-proliferative diabetic
retinopathy.
21
4 Sight-threatening Diabetic
Retinopathy
Sight-threatening diabetic retinopathy (Referable diabetic retinopathy) was defined as severe non-proliferative
diabetic retinopathy, proliferative diabetic retinopathy and clinically significant macular edema.
21
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The present study primarily reports the prevalence of
albuminuria (micro - and macro -) amongst persons
with type 2 diabetes and evaluates its role as a risk fac-
tor for presence and severity of DR. Besides, it also
reports the risk factors related to albuminuria as its sec-
ondary outcome measures.
In the present study, the age- and gender adjusted
prevalence of diabetes mellitus in a population older
than 40 years was 28.2%. Other studies have also shown
a similar high prevalence of diabetes mellitus from India
[22-24].
The National Urban Diabetes Study (2000) [25]
showed the prevalence of diabetes in a population older
than 40 years to be 23.8% in 6 cities in India including
Chennai, and more recently, the Chennai Urban Rural
Epidemiology Study (2003-2004) estimated the preva-
lence in those older than 40 years to be 30.1% [26].
In the present study, individuals with type 2 diabetes
showed prevalence of microalbuminuria to be around
16%, and that of macroalbuminuria, around 3%. It
means that every 6
th individual in the population of
individuals with diabetes had albuminuria. While occur-
rence of microalbuminuria was observed in equal pro-
portions in individuals with known diabetes vs. newly
diagnosed (16.4% vs. 14/1%), macroalbuminuria was
more common in the former group (3.1% vs. 0.8%). The
prevalence of micro - and macroalbuminuria was
reported to be around 27% and 5% by Unnikrishnan et
al [2]. Like the results of our study, they also noted that
individuals with known diabetes had higher prevalence
of macroalbuminuria than those with newly diagnosed
diabetes (6.5% vs 3.9%); no differences were noted with
regard to microalbuminuria.
Our study highlighted that subjects with microalbumi-
nuria were around 2 times as likely to have DR as those
without microalbuminuria, and this risk became almost
6 times in the presence of macroalbuminuria. A similar
trend was noted for sight-threatening DR, the odds were
2.5 times for microalbuminuria and 14 times for macro-
albuminuria. The DCCT in type 1 diabetes mellitus
reported that there is a relationship between DR and
diabetic nephropathy [27]. Within the study group that
showed evidence of minimal DR at baseline, 10% had
elevated UAE rates. For the population with type 2 dia-
betes, though the association between advanced degrees
of DR and macroalbuminuria (or proteinuria) is well-
known [5,13,14,28,29], the relationship with lower levels
of UAE within the range of microalbuminuria is contro-
versial. Some investigators have reported a positive asso-
ciation [5,28,30-33, while in other studies this has not
been observed [11,34-36]. Boelter et al [33] also
Table 2 Prevalence of Albuminuria in the Study Population
Groups Overall (N = 1414) KD* (N = 1166) NDD
† (N = 248) p for KD vs NDD
n (%) (95% CI) n (%) (95% CI) n (%) (95% CI)
Normoalbuminuria 1150 (81.3%) (79.3 - 83.3) 939 (80.5%) (78.2- 82.8) 211 (85.1%) (80.5-9.5) 0.095
Microalbuminuria 226 (15.9%) (13.9-17.8) 191 (16.4%) (4.2- 8.5) 35 (14.1%) (9.7-18.4) 0.376
Macroalbuminuria 38 (2.7%) (1.8-3.5) 36 (3.1%) (2.1- 4.0) 2 (0.8%) (-0.3-1.9) 0.044
* KD, Persons with known diabetes;
† NDD, Persons with newly diagnosed diabetes
Table 3 Clinical Characteristics of the Study Subjects
Variables* Normoalbuminuria
n = 1150
Microalbuminuria
n = 226
Macroalbuminuria
n=3 8
p
Male 609 (53.0) 118 (52.2) 23 (60.5) 0.631
Age (years) 55.7 ± 10.0 58.6 ± 9.6 59.6 ± 9.67 < 0.001
Duration of DM (years) 5.2 ± 6.1 6.6 ± 6.6 8.9 ± 6.2 < 0.001
BMI (kg/m2) 25.5 ± 3.9 24.9 ± 4.5 23.5 ± 3.8 0.004
SBP (mm of Hg) 137.4 ± 19.9 145.6 ± 22.8 150.4 ± 23.0 < 0.001
DBP (mm of Hg) 81.5 ± 11.2 84.0 ± 11.5 83.8 ± 12.9 0.005
HbA1c (gm %) 8.0 ± 2.1 9.0 ± 2.3 9.0 ± 2.3 < 0.001
Serum TC 186.1 ± 40.4 186.8 ± 39.3 196.5 ± 56.9 0.299
Serum HDL 39.2 ± 10.2 38.8 ± 9.3 42.5 ± 13.2 0.119
Serum TGL 153.4 ± 104.4 156.1 ± 80.4 148.9 ± 75.2 0.896
Presence of DR 162 (14.1) 70 (31.0) 23 (60.5) < 0.001
Presence of Sight threatening DR 16 (9.9) 15 (21.4) 14 (60.9) < 0.001
Abbreviations: DM, Diabetes Mellitus; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HbA1c, Glycosylated Hemoglobin; DR,
Diabetic Retinopathy
* Data are means ± SD or n (%)
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urinary albumin excretion within the microalbuminuria
range in type 2 diabetic patients with proliferative dia-
betic retinopathy. They emphasized that all patients
with proliferative diabetic retinopathy should undergo
an evaluation of renal function including urinary albu-
min measurements. A few studies have identified that
the renal changes seen in individuals with both microal-
buminuria and retinopathy had a distinct pattern com-
pared to those having microalbuminuria without
retinopathy. Severe retinopathy has been described as
more closely associated with glomerulosclerosis, with
Kimmelstiel-Wilson nodules, than with mesangial
sclerosis [37].
Logistic regression analysis identified increasing age,
raised blood pressure, and poor glycemic control as
influencing microalbuminuria. Though a very subtle
connection has been reported between urinary albumin,
DR and lipids [38], we did not find a significant associa-
tion between serum lipids and albuminuria in our study.
BMI was inversely related to macroalbuminuria, how-
ever, this finding may only reflect the worst nutritional
state of patients with more advanced renal disease and
not a causal relationship. A poor nutritional status has
been reported among subjects with diabetic nephropathy
due to many factors, including higher resting energy
expenditure, increased muscle protein breakdown [as
reported in patients with type 2 DM undergoing hemo-
dialysis] and, in some cases, restrictive dietary advice
[39]. Raised blood pressure also influenced macroalbu-
minuria. The EURODIAB study in type 1 diabetes melli-
tus showed that the correlation between increasing
blood pressure and albumin excretion rate was only
confirmed in patients who also had DR, independently
of glycemic control or diabetes duration, suggesting that
DR, in association with increased blood pressure, is an
important independent risk factor for diabetic nephropa-
thy progression [40]. Unnikrishnan et al [2] reported
association of systolic blood pressure with both micro-
and macroalbuminuric groups and diastolic blood pres-
sure with only microalbuminuric group. Poor glycemic
control as a risk factor form i c r o a l b u m i n u r i aw a s
reported in various studies [2,5,7]. Good glycemic and
hypertension control should be recommended to pre-
vent the occurrence of these complications of diabetes.
The association between microalbuminuria and DR
observed in the present study could be explained by the
view that microalbuminuria might represent a state of
generalized vascular dysfunction [41]. Enzymes involved
in the metabolism of anionic components of the extra-
cellular matrix (e.g. heparan sulphate proteoglycan) vul-
nerable to hyperglycaemia, seem to constitute the
primary cause of albuminuria and its associated compli-
cations. Genetic polymorphism of such enzymes [41], as
well as of several candidate genes [42-47] has been
hypothesized to be the main reason for the variation in
susceptibility.
Alternatively, microalbuminuria and DR may share
common risk factors. The duration of diabetes and
blood pressure levels are well-known risk factors for
both DR and diabetic nephropathy [48,49]. There are
other factors which damage vessels in both retina and
kidney. For example, Klein et al [50] showed that micro-
albuminuria could be seen in 29.2% of insulin taking
patients and 22% of non-insulin dependent patients.
Likewise, Kim et al [51] reported that fasting plasma
level of insulin and systolic blood pressure has indepen-
dent correlation with microalbuminuria. Besides com-
mon mechanisms, renal damage may accelerate
retinopathy which is associated with serum levels of
fibrinogen and lipoproteins [52]. Also, albuminuria has
been considered as a predictor of DR and coronary
heart disease [53].
There are potential shortcomings in our study that
require comment. A major limitation was the use of sin-
gle urine sample for estimation of microalbuminuria for
Table 4 Multiple Logistic Regression Analysis of Risk Factors for Albuminuria
Variables Microalbuminuria Macroalbuminuria
Odds ratio (95% CI) p* Odds ratio (95% CI) p*
Age (per year) 1.02 (1.00 - 1.04) 0.005 1.02 (0.98 -1.06) 0.280
Duration of DM ((per year) 1.00 (0.97 -1.02) 0.869 1.02 (0.97 - 1.07) 0.358
BMI (per Kg/m
2) 0.97 (0.93-1.01) 0.207 0.89 (0.80-0.98) 0.028
SBP (per mm of Hg) 1.01 (1.00-1.02) 0.008 1.02 (1.00- 1.04) 0.014
DBP (per mm of Hg) 1.01 (0.99-1.03) 0.180 1.00 (0.97-1.04) 0.817
HbA1c (per gm %) 1.18 (1.11-1.26) < 0.001 1.07 (0.92-1.25) 0.352
Presence of DR 2.10 (1.46-3.01) < 0.001 6.50 (3.11-13.61) < 0.001
Presence of Sight threatening DR 2.49 (1.15-5.37) 0.02 14.19 (5.31-37.96) < 0.001
Abbreviations: DM, Diabetes Mellitus; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HbA1c, Glycosylated Hemoglobin; DR,
Diabetic Retinopathy
*Adjusted for age, duration of diabetes, body mass index, SBP, DBP and HbA1c
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ences drawn as most epidemiological studies have
followed methodology of single urine sample measure-
ments. Another limitation is its cross-sectional design.
Renal involvement is a strong predictor of mortality
[54], also in population-based patient samples. Therefore
life-time prevalence of renal involvement is much
greater than the prevalence found in our cross-sectional
survey. Besides, we did not confirm the presence of type
2 diabetes by studying the auto-antibodies, hence it is
difficult to believe that our study population consisted
of subjects with type 2 diabetes only. Moreover, the cur-
rent diagnosis of type 2 diabetes according to ADA is
fasting plasma glucose (FPG) > = 126 mg/dL. Thus, the
previous classification used in the present study (FPG >
= 110 mg/dL) permitted the inclusion of patients with
impaired glucose tolerance and impaired fasting glucose
among the diabetic patients. The presence of retinopa-
thy characteristic of diabetes has been reported in 12.6%
of persons with elevated fasting glucose and impaired
glucose tolerance and no known history of diabetes, in
comparison to 7.9% of nondiabetic persons [55]. The
presence of isolated microalbuminuria is also believed to
be a biomarker of widespread vascular injury and ather-
osclerotic burden. In this sense, it does not measure a
“kidney disease” per se, but only a secondary and indir-
ect effect of a distant disease process on kidney physiol-
ogy [56]. Thus, microalbuminuria is more a marker of
endothelial dysfunction instead of a marker of renal
impairment [57-59]. This fact may also explain why
newly diagnosed patients (who probably present other
cardiovascular risk factors) presented a rate of microal-
buminuria similar to the one observed in the group with
known diabetes, while only macroalbuminuria, a more
specific marker of renal impairment was significantly
different between the two groups.
The strengths of the study are a well-conducted popu-
lation-based prevalence study, with retinopathy diagno-
sis based on gold standard fundus photography and
comprehensive clinical and biochemical evaluation.
It must be remembered that renal involvement only
identifies a group of diabetic patients at high risk of
developing complications, including DR, and these
patients may benefit from intensive treatment [60].
Identification of renal involvement cannot be used to
narrow down the number of patients who need to be
screened for DR, as many patients without renal invol-
vement have DR.
Conclusions
Micro - or macroalbuminuria are highly prevalent in
subjects with type 2 diabetes with every sixth individual
having some albuminuria. Subjects with micro - and
macroalbuminuria are more likely to have DR as those
without albuminuria.
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